2024
Survivorship Care for People Affected by Advanced or Metastatic Cancer: MASCC-ASCO Standards and Practice Recommendations
Hart N, Nekhlyudov L, Smith T, Yee J, Fitch M, Crawford G, Koczwara B, Ashbury F, Lustberg M, Mollica M, Smith A, Jefford M, Chino F, Zon R, Agar M, Chan R. Survivorship Care for People Affected by Advanced or Metastatic Cancer: MASCC-ASCO Standards and Practice Recommendations. JCO Oncology Practice 2024, 20: 1160-1172. PMID: 38684036, DOI: 10.1200/op.23.00716.Peer-Reviewed Original ResearchQuality survivorship careSurvivorship carePractice recommendationsUnmet supportive care needsPalliative care frameworkSupportive care needsSystematic reviewModified Delphi consensus processPerson-centered careEnd of lifeData-driven careMultinational Association for Supportive CareDelphi consensus processSupportive careCancer survivorshipCare goalsIntegrated careCare experiencesCare needsCare frameworkHealth outcomesCommunicating careResourcing carePerson-centeredConsensus process
2021
Limited benefit and high financial burden of drugs used to manage cancer-associated anorexia/cachexia syndrome (CACS).
Gupta A, Nshuti L, Grewal U, Sedhom R, Parsons H, Blaes A, Virnig B, Lustberg M, Subbiah I, Nipp R, Dy S, Dusetzina S. Limited benefit and high financial burden of drugs used to manage cancer-associated anorexia/cachexia syndrome (CACS). Journal Of Clinical Oncology 2021, 39: 55-55. DOI: 10.1200/jco.2020.39.28_suppl.55.Peer-Reviewed Original ResearchPrescription drug coverageAnorexia/cachexia syndromeDrug coveragePocket costsRisk/benefit ratioPatient-clinician discussionsSupportive care guidelinesFinancial burdenList of drugsCost of drugsUse of drugsHigh financial burdenEnd of lifeCachexia syndromeCare guidelinesUnwanted side effectsGeneric olanzapineSide effectsClinical practiceCertain drugsMultiple drugsStudy authorsBenefit ratioDrugsLimited benefit